thelinke/E+ via Getty Images Shares of AstraZeneca (NASDAQ:AZN) declined earlier this week after the company and its partner Daiichi Sankyo (OTCPK:DSNKY) presented disappointing overall survival data from the phase 3 trial of the antibody-drug conjugate (‘ADC’) candidate datopotamab deruxtecan, or Dato-DXd, in patients with advanced non-squamous non-small cell lung cancer. Dato-DXd is part of AstraZeneca’s expanding ADC pipeline, and part of a greater effort to offer better treatment options for lung ca ...